Abstract. To understand the molecular pathogenesis of ossification of the posterior longitudinal ligament of the spine (OPLL), an ectopic bone formation disease, we performed cDNA microarray analysis on cultured ligament cells from OPLL patients to understand the molecular pathogenesis of OPLL. We identified promyelotic leukemia zinc finger (PLZF) as one of upregulated genes and tumor necrosis factor-α-stimulated gene 6 (TSG-6) as one of down-regulated gene during osteoblastic differentiation. We investigated the roles of PLZF in the regulation of osteoblastic differentiation of human mesenchymal stem cells (hMSCs) and C2C12 cells. siRNAmediated gene-silencing of PLZF resulted in a reduction of the expression of osteoblast-specific genes such as the alkaline phosphatase, collagen 1A1, Runx2 / CBFA1, and osteocalcin genes in the presence of osteogenic differentiation medium (OS) in hMSCs. The overexpression of PLZF induced CBFA1 induction, suggesting that PLZF is an upstream regulator of CBFA1 and thereby participates in promoting the ossification of spinal ligament cells in OPLL patients. Adenoirusmediated TSG-6 overexpression in hMSCs resulted in suppression of oseoblastic differentiation induced by either BMP-2 or OS. TSG-6 can bind to BMP-2 directly and thereby could inhibit BMP-2 signaling. Taken together, these findings indicate that PLZF and TSG-6 play important roles in early osteoblastic differentiation.
Introduction
Ossification of the posterior longitudinal ligament of the spine (OPLL) is a subset of bone forming disease, characterized by ectopic ossification in the spinal ligaments. OPLL is a common disorder among elderly populations in East Asia, and the leading cause of impairments to spinal cord function in Japan (1, 2) . Despite the late onset (average age of onset: 50 years), OPLL has a strong genetic background as shown in classical epidemiological studies and by an estimate of relative risk to siblings of about 10 (2, 3). Because genetic factors appear to play crucial roles in the etiology of OPLL, genetic screenings to identify susceptibility are important. Thus far we have performed genetic linkage and linkage disequilibrium studies to identify susceptibilities of OPLL and successfully identified the collagen 11A2 gene (COL11A2) and collagen 6A1 gene (COL6A1) (3 -6) . We also demonstrated that the intron 6 (-4A) polymorphism of COL11A2 affects splicing of exon 6 in ligament cells from OPLL patients (5) . Although the identification of genetic factors of OPLL provided important implications, the overall picture of the molecular pathogenesis is still unclear mainly because a subtle biological effect of the variant is the only observation and therefore the biological significance of the variant is still obscure. Accordingly, multiple approaches are needed to understand the etiology of OPLL. To elucidate the molecular pathogenesis of OPLL, cultured ligament cells from OPLL patients and non-OPLL controls were induced to undergo osteoblastic differentiation by osteogenic differentiation medium (OS) and then the gene expression profile was monitored by cDNA microarray analysis. Among the up-regulated genes during osteoblastic differentiation, we focused our attention on zinc finger protein 145 gene, also known as PLZF (promyelotic leukemia zinc finger), and demonstrated that PLZF promoted osteoblastic differentiation of human mesenchymal stem cells (hMSCs) as an upstream transcription regulator of corebinding factor gene (CBFA1). We also surveyed downregulated genes during osteoblastic differentiation and focused our attention on tumor necrosis factor α (TNF-α)-stimulated gene 6 gene (TSG-6) as a novel suppressor of osteoblastic differentiation in ligament cells from OPLL patients and hMSCs.
cDNA microarray analysis of OPLL and non-OPLL cells after OS treatment Cultured ligament cells from the spinal ligament of OPLL patients showed enhanced alkaline phosphatase (ALP) activity after OS induction compared to the cells from non-OPLL patients, demonstrating that OPLL cells have a strong tendency to differentiate into osteoblastic lineage compared with non-OPLL cells. The temporal pattern of gene expression during osteoblastic differentiation at an early stage (48-h post-OS treatment) was examined with a cDNA microarray that covers 12,814 distinct cDNA sequences of human genes Fig. 1 . Osteoblastic differentiation of primary ligament cells from OPLL and non-OPLL patients was monitored by cDNA microarray analysis. Cells were cultured for 24 h in the presence or absence of 0.1 µM dexamethasone, 10 mM β-glycerophosphate, and 0.05 mM ascorbic acid (OS) and then prepared for mRNA labeling. Differences in gene expression profile during osteoblastic differentiation were investigated by the use of cDNA microarray prepared by Agilent Technologies. mRNA was labeled with Cy3 (w /o OS induction) and Cy5 (w OS induction) and hybridized with cDNA microarray. The microarrays were scanned in both Cy3 and Cy5 channels with Agilent microarray scanner.
( Fig. 1) . A total of about 3000 genes were observed with positive signals in undifferentiated primary cells. Thirty genes were up-regulated more than 2-fold in OPLL cells during osteoblastic differentiation. The genes including these for metallothionein, crystallin αB, and adrenomudullin were up-regulated more than 2-fold in all the cells. PLZF was one of the most prominently up-regulated genes after addition of OS in the cDNA microarray analysis. Thirty-two genes were down-regulated during osteoblastic differentiation, including trinucleotide repeat containing 3, TSG-6, hypoxiainducible factor 1 α subunit, and P311 protein. Among them, TSG-6 expression after OS treatment decreased 0.25-fold for OPLL cells, and 0.48-fold in non-OPLL cells. The promoting and suppressive effects of PLZF and TSG-6, respectively, on osteoblastic differentiation were further investigated.
Expression of PLZF and TSG-6 in hMSCs after OS treatment
hMSCs exhibit pluripotent differentiation and differentiate into the osteogenic lineage in the presence of OS (7). RT-PCR analysis confirmed that the expression of PLZF was highly elevated in hMSCs at day 2 of OS treatment (data not shown). TSG-6 is sharply downregulated during osteoblastic differentiation induced by OS and the decreased expression is more prominent in hMSCs than in the ligament cells. RT-PCR analysis confirmed the prolonged down-regulation of TSG-6 up to 3 days (data not shown).
Effect of siRNA targeting PLZF on osteoblastic differentiation in hMSCs
Two siRNAs targeting PLZF were prepared ( Fig. 2a ) (8, 9) and transfected into OS-treated hMSCs with the lipofection method. Introduction of the two siRNAs targeting PLZF resulted in a down-regulation of the PLZF expression, while GFP-targeted siRNA as a control did not affect the expression of PLZF (Fig. 2b) . siRNA-mediated gene-silencing of PLZF suppressed the expression of osteoblast-specific genes, ALP, collagen 1A1 (COL1A1), and osteocalcin (OCN) genes and the mineralized matrix formation, suggesting that PLZF has an important role in the osteoblastic differentiation ( Fig. 2: b and c) . The reduced expression of core binding factor α1 (CBFA1) after gene-silencing of PLZF in OS-treated hMSCs was confirmed by immunohistochemistry, indicating that PLZF might act as an upstream regulator for CBFA1 (Fig. 2: b and d) .
Effect of overexpression of PLZF on the osteoblastic differentiation of C2C12 cells C2C12, a well-established mouse cell line capable of osteoblastic differentiation, was used for an overexpression experiment because hMSCs could not be efficiently transfected. Over-expression of PLZF in C2C12 cells (Fig. 3a) resulted in an elevated expression of CBFA1, COL1A1, and OCN (Fig. 3b) . COL1A1 and ALP expression, confirmed based on either immunohistochemistry or enzyme activity, was enhanced after over-expression of the full-length PLZF (Fig. 3: c and e) . Over-expression of PLZF in C2C12 cells promoted the expression of the CBFA1 transcript and protein (Fig. 3:  b and d) . Inversely, we examined the effect of CBFA1 on the expression of PLZF in C2C12 cells. Over-expression of CBFA1, confirmed from its transcript and protein levels, did not induce the expression of PLZF in C2C12 cells (data not shown). These findings suggest that PLZF is an upstream regulator of CBFA1.
Overexpression of TSG-6 inhibits osteoblastic differentiation of hMSCs
Adenovirus vector carrying TSG-6 cDNA was infected into hMSCs and effects of overexpression of TSG-6 on the osteoblastic differentiation were investigated. Overexpression of TSG-6 was confirmed by either RT-PCR (Fig. 4a) or protein staining and immunoblotting with anti-FLAG antibody (Fig. 4b) . Twenty-four hours after the adenovirus vector infection, the hMSCs were subjected to osteoblastic induction by BMP-2 or OS, and then the effect of the TSG-6 overexpression on the osteoblastic differentiation was examined by ALP staining on day 5 after the induction. The overexpression of TSG-6 resulted in suppression of ALP enhancement induced by BMP-2 as well as OS (Fig. 4c) . In addition, the overexpression of TSG-6 resulted in reductions of osteoblast-specific genes such as ALP and COL1A1 in the presence of BMP-2 (100 ng / ml) for 3 days (Fig. 4d) . In hMSCs, BMP-2-induced expression of CBFA1, a pivotal transcription factor of osteogenesis, was unaffected by the TSG-6 overexpression. Figure 4e shows that the overexpression of TSG-6 resulted in a marked suppression of type I collagen protein expression induced by BMP-2. Taken together, these results indicate that TSG-6 is a suppressive regulator of the osteoblastic differentiation of hMSCs.
TSG-6 inhibits BMP-2-signaling by direct binding
TSG-6, an extracellular glycoprotein, could possibly suppress BMP-2-induced osteoblastic differentiation of hMSCs through inhibition of BMP-2/ the receptor binding. To test whether TSG-6 protein can directly interact with BMP-2, FLAG-tagged TSG-6 in conditioned medium of 293F cells were incubated with recombinant BMP-2 and in vitro binding was examined by immunoprecipitation with an anti-FLAG antibody followed by immunoblot analysis with an anti-BMP-2 antibody to detect TSG-6 protein-bound BMP-2. As shown in Fig. 4f , TSG-6 proteins directly interacted with BMP-2 in vitro.
Role of PLZF and TSG-6 in the pathogenesis of OPLL
A bone loss disease, osteoporosis is the opposite of OPLL and indeed has been observed in OPLL patients at low frequency compared with subjects of similar ages. Therefore, elucidation of the molecular etiology of OPLL might permit us to develop novel therapeutic tools for osteoporosis as well. To date the genetic approach with family and case-control studies has identified COL11A2 and COL6A1 as susceptibilities to OPLL (3, 6) . Interestingly, extracellular matrix proteins appear to play important roles in the ossification process. Despite that the disease-related variant of COL11A2 resulted in an altered splicing efficiency (5), the biological impact of the variants that leads to OPLL remains unknown. Bone is a dynamic tissue showing continuous formation and resorption that are recognized as bone remodeling. OPLL is characterized by ectopic bone formation in the ligament through both endochondral and intramembranous ossification mechanisms and also a systemic high bone mass (2) . An imbalance between bone formation and resorption may shape a key etiology underlying OPLL, thereby genes of positive and negative regulators of the bone formation play equally important roles in the ectopic ossification.
We identified several genes of interest that were upregulated or down-regulated during osteoblastic differentiation using cDNA microarray analysis (Fig. 1) . PLZF was one of the most prominently up-regulated genes in OPLL and after OS treatment, while TSG-6 was identified as a down-regulated gene. Recently, several zinc finger genes were reported to play important roles in bone formation such as Osterix (10), AJ18 (11), and CIZ (12) . In addition, a series of zinc finger transcription factors of unknown function was identified in a cDNA microarray analysis after osteoblastic differentiation in human mesodermal progenitor cells (13) . We investigated the functional significance of PLZF in osteoblastic differentiation. We also demonstrated that TSG-6 is a suppressive regulator of osteoblastic differentiation of ligament cells from OPLL patients as well as hMSCs (Figs. 1 and 4) . , and CBFA1 transcripts in hMSCs. The adenovirus-infected hMSCs were induced by BMP-2. Three days later, total RNA was extracted, and the RT-PCR was performed with specific primers. e: Protein level of type I collagen in hMSCs. Adenovirus-infected hMSCs were induced by BMP-2. Three days later, the cellular protein was extracted and immunoblot analysis was performed. f: In vitro interaction between BMP-2 and TSG-6 proteins. To determine if TSG-6 protein can interact directly with BMP-2, the TSG-6-overexpressed conditioned medium of 293F cells was incubated with recombinant BMP-2, and in vitro binding was examined by immunoprecipitation to detect TSG-6 protein-bound BMP-2.
PLZF belongs to the POZ / zinc-finger family of transcription factors. In order to examine the functional role of PLZF in osteoblastic differentiation, hMSCs were subjected to osteoblastic differentiation and the involvement of PLZF was investigated. PLZF expression was dramatically enhanced by OS and PLZF expression appears to be an early event in osteoblastic differentiation. siRNA-mediated gene-silencing of PLZF inhibited the osteoblastic differentiation of hMSCs (Fig. 2) . In turn, over-expression of PLZF in C2C12 cells led to elevated levels of CBFA1 and other bone marker genes and siRNA-mediated gene-silencing of CBFA1 abolished the inductions of marker genes (Fig. 3) . These results strongly indicate that PLZF is a key regulator of osteoblastic differentiation and acts as an upstream activator of CBFA-1 because over-expression of CBFA1 did not affect the expression of PLZF (data not shown).
TSG-6 is tightly regulated by TNF-α, a potent proinflammatory cytokine ubiquitously distributed throughout the body. Expression of TNF-α is involved in bone resorption through activation of osteoclasts, particularly in inflammatory bone diseases. High levels of TNF-α were documented in tissues derived from peri-prosthetic osteolysis and joint arthritis (14) . TNF-α exposure of pre-osteoblasts from stromal or calvarial origin strongly inhibits differentiation of these cells into mature matrixproducing osteoblasts (15) . In hMSCs, we observed upregulation of TSG-6 after TNF-α treatment, suggesting that the inhibitory effect of TNF-α on OS-induced osteoblastic differentiation is possibly mediated by stimulated expression of TSG-6. Because the pathway involved in BMP-induced osteoblastic differentiation has been extensively characterized, we focused our investigation on the roles of TSG-6 in BMP-2-induced osteoblastic differentiation. The adenovirus vectormediated overexpression of TSG-6 in hMSCs blocked BMP-induced osteoblastic differentiation as shown in suppressive expressions of COL1A1 and ALP. These actions of TSG-6 are expected to shift the formation / resorption balance in the skeleton toward resorption, which might explain, at least in part, the bone loss in inflammatory arthritis.
Conclusion
In conclusion, PLZF and TSG-6 identified as an upregulated gene and down-regulated gene, respectively, during the osteoblastic differentiation of OPLL cells play important roles in the early stage of osteoblastic differentiation in hMSCs. The molecular pathways by which PLZF and TSG-6 exert their functions in bone formation are still under investigation, and elucidation of these pathways will facilitate the development of novel therapeutic tools for both bone-forming and boneloss diseases.
